First Opinion By Jen Goldsack, Rachel A. Chasse, and William A. Wood Digital endpoints library can aid clinical trials for new medicines
First Opinion By Julie Rehmeyer and David Tuller Why did it take the CDC so long to reverse course on debunked treatments for chronic fatigue syndrome?
First Opinion By Julie Rehmeyer Bad science misled millions with chronic fatigue syndrome. Here’s how we fought back
First Opinion By Nancy A. Dreyer Real-world evidence is changing the way we study drug safety and effectiveness
Pharma By Rebecca Ritzel FDA pushes drug companies to include younger people in breast cancer drug trials
First Opinion By Joseph S. Ross, Joanne Waldstreicher, and Harlan M. Krumholz Sharing clinical trial data: lessons from the YODA Project
Pharmalot By Ed Silverman Flawed trials supported half of recent approvals of cancer drugs in Europe, study says
First Opinion By Bobby Clark and Ronnie Tepp Community engagement is key to clinical trial recruitment and diversity
First Opinion By Louise Aronson A new NIH rule won’t be enough to make clinical research more inclusive
First Opinion By Jane L. Delgado and Edward Abrahams Diversity in clinical trials defines good science and better medicine
First Opinion By Jeremy Farrar It isn’t crazy to conduct an Ebola clinical trial in a war zone — it’s necessary
Pharmalot By Ed Silverman Pharmalittle: Trump to require drug prices in ads; Europe cracks down on valsartan ingredients maker
First Opinion By Julia G. Brody All study participants have a right to know their own results. My lab has been doing that for years
First Opinion By Jake LaPorte Digital technologies hold the key to streamlining and improving clinical trials
Lessons Learned By Megha Satyanarayana Lessons Learned: This is how you take a public health degree to a startup and back to academia
Pharmalot By Ed Silverman Millions in fines are adding up as clinical trial information goes unreported
Biotech By Adam Feuerstein Dermira discontinues development of acne drug after two late-stage trials fail
First Opinion By Howard M. Fillit FDA’s updated standards remove an unnecessary barrier to testing Alzheimer’s drugs
In the Lab By Andrew Joseph How well can you predict the outcome of clinical trials? Not as well as you may think
Health By Marisa Taylor — Kaiser Health News Unregulated herpes experiments expose ‘black hole’ of accountability
Biotech By Adam Feuerstein Nabriva novel antibiotic meets goals in late-stage bacterial pneumonia study
Business By Adam Feuerstein Stakes are high as Alnylam awaits results from novel rare disease therapy
Business By Adam Feuerstein 5 things to know about Sage’s must-win drug trials in postpartum depression
Pharma By Adam Feuerstein AstraZeneca immunotherapy study shows benefit for niche group of lung cancer patients